[ad_1]
Adhesive for the Treatment of Alzheimer's Disease is Now Available by SUS
A new form of treatment for Alzheimer's Disease is available in the SUS. Rivastigmine, already available in tablets and oral solution, is now available in transdermal form.
Rivastigmine causes an increase in the substance called acetylcholine, which is reduced in the brains of patients with Alzheimer's disease, but the drug can cause gastrointestinal symptoms such as nausea and diarrhea, decreased appetite and headaches.
The addition of the adhesive to the SUS drug list represents an improvement in the quality of life of some patients. According to Rodrigo Schultz, president of the Brazilian Association of Alzheimer's Disease, the adhesive also ensures that there is no evidence of side effects. Dose fluctuation: "Being transdermal, there is a continuous and regular release during the 24 hours, preventing the occurrence of dose fluctuation, increases and decreases of the drug in the body while the patient is being treated. it continues to be metabolized. "
According to Schultz, many patients refuse to use oral medications and often take medication from their own mouths after administration.
" With the stamp he can not do that. In addition, as the absorption is cutaneous, there is a significant reduction in the possibility of side effects, mainly gastrointestinal. "
Alzheimer's is a neurodegenerative disease, caused by the progressive death of brain cells, impairing functions such as memory, attention and orientation and language, which has serious consequences on quality of life of patients.
Adhesive for the treatment of Alzheimer's disease is already available by SUS
In Brazil, according to 2017 data, it is estimated that there There are 1.1 million people with the disease [19659003]
Any patient with Alzheimer's disease who is taking rivastigmine can use the drug in an adhesive version: " There is a population that benefits more than the one who has difficulty swallowing or presenting, "explains Schultz
The patch can also be used in the bath and must be removed 24 hours after use. 39 it is placed on the skin, the patch may occasionally cause reactions at the site of its establishment and therefore a rotation on the site of use of the patch is recommended
"In case of failure, tablets or oral solution may be used . no problem.
According to the Ministry of Health, the drug is already available in the health units responsible for the distribution of this type of medicine.
According to the department, patients must meet the eligibility criteria for clinical protocols and therapeutic guidelines and submit the following documents to a designated health facility:
– copy of national card of Health (CNS)
–
– Report on the application, evaluation and authorization of drugs of the specialized component of pharmaceutical badistance (LME), duly completed
– duly completed medical prescription
– documents required in the Nicos Cl Protocols and therapeutic guidelines published in the final version by the Ministry of Health, disease and the requested medication;
In addition to rivastigmine, SUS also provides other drugs for the treatment of Alzheimer's disease: Donepezil, Galantamine and Memantine.
The department explains that the addition of the adhesive version of the to the list provided by SUS is due to the lower side effects and the ease of application.
"Rivastigmine was already offered orally, but had the disadvantage of causing gastrointestinal discomfort in the patient, such as nausea, vomiting, and diarrhea.To try to reduce these side effects, this new presentation been incorporated, which will be indicated by the doctor accompanying the patient.In addition, patients with Alzheimer's disease may take more drugs or less than the prescribed amount due to forgetfulness, "says a note from the Ministry of Health.
Source link
